Colon cancer patients with family history have better survival rates when receiving on time treatment compared to those with no family history of colon cancer.

The prevalence of pre-cancerous masses in the colon is the same for average-risk patients who are 40 to 49 years of age and those who are 50 to 59 years of age, therefore making it important to have colon cancer screening at a younger age.

Thousands Of colorectal cancer patients benefit from Avastin-based therapy.

Among patients at increased risk for colorectal cancer who completed an annual fecal immunochemical test, detection of cancerous lesions occurred an average of 26.5 months earlier than would have occurred during the three-or five-year study-required colonoscopy.

Large, open incisions that cause pain and require lengthy healing times might be unnecessary to treat colorectal cancer patients successfully.

GeneNews reported positive performance results from a large validation study of a six-gene biomarker panel for the assessment of a patient's current risk for colorectal cancer. This panel forms the basis of the Company's lead product, ColonSentry, which is planned for launch in Canada in the third quarter of 2008 as a laboratory-developed test.

The validation study confirmed (p less than 0.05) that the panel was able to stratify a population with average risk for colorectal cancer into three groups:

-

Colon cancer screening is a tough sell.

In eligible patients Eloxatin in combination with 5-fluorouracil/leucovorin significantly improved three-year PFS compared to surgery alone when given perioperatively to colorectal cancer patients with initially resectable liver metastases.

Early colon cancer detection is the key to its cure.

research has found an association between certain microRNA expression patterns and poor survival and treatment outcomes for colon cancer.

Genomic Health announced results of studies that have identified genes that could help predict the likelihood of recurrence and chemotherapy benefit for early-stage colon cancer.

ASGE encourages all men and women age 50 and over to add getting screened for colorectal cancer to their list of New Year's resolutions for 2008.

A majority of Americans who should be getting screened for colorectal cancer are not being screened for colon cancer.

The low overall colorectal cancer screening rates are consistent with previous studies, and that a majority of Medicare beneficiaries received incomplete or no colorectal cancer screening.

CC Detect, Panacea Pharmaceuticals's serum- based colon cancer diagnostic test, is now available from Panacea Laboratories. CC Detect is a simple blood test that should facilitate the identification of individuals with cancer of the colon and rectum when used in conjunction with standard screening methods. Panacea Laboratories, a division of Panacea Pharmaceuticals, is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). The blood sample can be ordered by any physician and sent to Panacea for testing.